Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Society to Request 3-month Prescription Periods for Anti-HIV Drugs
February 19, 2001
- Price of Seroquel Is 4 Times Higher Than Lullan
February 19, 2001
- RA Patient Group Holds Survey on Clinical Trials
February 19, 2001
- Long, Short-term Goals Must Be Set for Reform: JMA President
February 19, 2001
- Asthma Telemedicine Should Reduce Asthma Deaths: Teijin Seminar
February 19, 2001
- Chugai's '75-year History' Published
February 19, 2001
- Standard Drug Name, Lab Test Masters Completed
February 19, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
February 19, 2001
- Locate in Scotland, Scottish Trade International Move to New Office
February 19, 2001
- Average Bungyo Rate for All Programs Exceeds 40% for First Time
February 19, 2001
- Korosho Denies Need for Further Deregulation
February 19, 2001
- Sumitomo Revises Sales for 2002 Upward to \150 Billion: President Yokotsuka
February 19, 2001
- FPMAJ Drafts GL for Distinctive Labeling of Paper, Plastic Packages
February 19, 2001
- J&J Pushes Sales of Tylenol Series
February 19, 2001
- Fujisawa Aims at Top Share in Market for Psychotropics
February 19, 2001
- Guide to Prepare NDA Dossiers According to CTD Published
February 19, 2001
- Rohto to Introduce Sliming Supplement from Italy
February 19, 2001
- Santen Licenses in Anti-APO-1 Antibody from Centocor
February 19, 2001
- REGULATORY NEWS IN BRIEF -1-
February 19, 2001
- DyDo to Aggressively Expand Drugstore Business
February 19, 2001
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…